A study to evaluate the immunogenicity, safety and reactogenicity of adjuvanted influenza vaccine candidates compared to Fluarix administered intramuscularly in subjects aged 18−59 years.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2018
At a glance
- Drugs GSK 1247446A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 13 Feb 2007 Status change
- 14 Dec 2006 New trial record.